We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-1.16%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.86B
AUM Growth
+$4.04B
Cap. Flow
+$4.05B
Cap. Flow %
69.18%
Top 10 Hldgs %
42.44%
Holding
220
New
83
Increased
86
Reduced
22
Closed
19

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$541M
2
INCY icon
Incyte
INCY
+$293M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$290M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$228M
5
SAGE
Sage Therapeutics
SAGE
+$223M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$28.3M
2
COR icon
Cencora
COR
+$19.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$16.5M
4
WBA
Walgreens Boots Alliance
WBA
+$14.7M
5
ILMN icon
Illumina
ILMN
+$9.58M

Sector Composition

Rank Sector Weight
1 Healthcare 94.72%
2 Technology 0.56%
3 Industrials 0.42%
4 Financials 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
101
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.46M 0.11%
268,500
+109,700
+69% +$2.78M
RMD icon
102
ResMed
RMD
$28.9B
$6.42M 0.11%
52,626
-2,041
-4% -$226K
VCRA
103
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$6.18M 0.11%
193,634
+35,420
+22% +$1.13M
SILK
104
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$6.14M 0.1%
+126,810
New +$5.39M
SWAV
105
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$5.57M 0.1%
97,547
-2,453
-2% -$119K
AGN
106
DELISTED
Allergan plc
AGN
$5.38M 0.09%
+32,100
New +$4.44M
SGEN
107
DELISTED
Seagen Inc. Common Stock
SGEN
$5.05M 0.09%
73,000
+27,200
+59% +$1.9M
MTLS
108
Materialise
MTLS
$379M
$4.7M 0.08%
240,770
-27,639
-10% -$451K
STIM icon
109
Neuronetics
STIM
$113M
$4.06M 0.07%
324,779
+29,442
+10% +$416K
HSIC icon
110
Henry Schein
HSIC
$10B
$4.05M 0.07%
57,917
+7,255
+14% +$480K
PEN icon
111
Penumbra
PEN
$12.5B
$4.03M 0.07%
25,180
+1,543
+7% +$223K
CDTX
112
DELISTED
Cidara Therapeutics
CDTX
$3.86M 0.07%
+114,764
New +$4.77M
A icon
113
Agilent Technologies
A
$37.1B
$3.79M 0.06%
+50,782
New +$3.76M
PTCT icon
114
PTC Therapeutics
PTCT
$6.52B
$3.76M 0.06%
83,500
+48,800
+141% +$1.93M
CHRS icon
115
Coherus Oncology
CHRS
$216M
$3.68M 0.06%
166,635
-150,500
-47% -$2.61M
AVTR icon
116
Avantor
AVTR
$7.56B
$3.57M 0.06%
+187,231
New +$3.33M
ZLAB icon
117
Zai Lab
ZLAB
$2.28B
$3.49M 0.06%
100,000
+70,000
+233% +$2.06M
CVS icon
118
CVS Health
CVS
$137B
$3.23M 0.06%
59,326
+1,699
+3% +$91.5K
SYNH
119
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$3.17M 0.05%
62,000
+14,800
+31% +$689K
KURA icon
120
Kura Oncology
KURA
$964M
$2.86M 0.05%
145,200
+115,900
+396% +$1.92M
ACAD icon
121
Acadia Pharmaceuticals
ACAD
$4.38B
$2.77M 0.05%
103,800
– –
ARNA
122
DELISTED
Arena Pharmaceuticals Inc
ARNA
$2.75M 0.05%
46,917
– –
CSLT
123
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$2.58M 0.04%
800,000
-1,020,470
-56% -$3.51M
BNFT
124
DELISTED
Benefitfocus, Inc.
BNFT
$2.39M 0.04%
88,163
+65,184
+284% +$2.19M
BLUE
125
DELISTED
bluebird bio
BLUE
$2.31M 0.04%
1,405
-378
-21% -$654K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2019 Portfolio in Review

As of Q2 2019, Bellevue Group held 220 positions worth $5.86B, up 222% from $1.82B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group deployed $4.05B of net new capital in Q2 2019, opening 83 new positions and adding to 86 existing holdings. Its largest new stake was Agios Pharmaceuticals: 3,128,134 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Wellcare Health Plans, Inc., an estimated $28.3M trimmed.

  • Bellevue Group's largest Q2 2019 buy was Agios Pharmaceuticals: 3,128,134 shares worth $156M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q2 2019, an estimated $541M increase.
  • Bellevue Group's biggest Q2 2019 reduction was Wellcare Health Plans, Inc., cutting an estimated $28.3M.
  • Bellevue Group fully exited Cencora in Q2 2019, selling an estimated $19.9M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.86B portfolio in Q2 2019.
  • Bellevue Group opened 83 new positions and closed 19 in Q2 2019.
  • Bellevue Group's portfolio value rose 222% quarter-over-quarter to $5.86B.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.